Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add filters








Language
Year range
1.
Chinese Journal of Immunology ; (12): 801-809, 2018.
Article in Chinese | WPRIM | ID: wpr-702821

ABSTRACT

Immune cell trafficking is a fundamental feature and common phenomenon in immunity. The dynamic trafficking of immune cells and interactions among immune cells and microenvironmental stromal cells underlie various immune events and play important roles for immune development and function. In this review,the major and representative progresses in this field in recent years were summarized and discussed.

2.
Acta Academiae Medicinae Sinicae ; (6): 67-72, 2005.
Article in Chinese | WPRIM | ID: wpr-343765

ABSTRACT

<p><b>OBJECTIVE</b>To investigate the immune responses and protection from virus challenge, induced by the coinjection of IL-2cDNA with herpes simplex virus type 1 (HSV-1) glycoprotein-D (gD) DNA vaccine.</p><p><b>METHODS</b>Two DNA vaccines (pgD and pIL-2) were constructed by inserting the gD gene and IL-2 cDNA into the eukaryotic expression vector pcDNA3.1, respectively. The BALB/c mice were inoculated intramuscularly three times at 2-week intervals. Two weeks after the final immunization, mice were bled for antibody assay and spleen cells were separated for Th cell proliferation and cytokine assays. Delayed type hypersensitivity (DTH) response was detected by the pinna-swelling test. Corneal protection under HSV-1 virus challenge was continuously observed with slit-lamp microscope.</p><p><b>RESULTS</b>IL-2 cDNA coinjection remarkably enhanced the specific IgG2a level when compared with gD plasmid vaccination alone. Th cell proliferation and secretion of cytokines (IL-2 and IFN-gamma) were significantly increased by IL-2 cDNA coinjection. However, the production of IL-10 was inhibited. The DTH response was also enhanced by IL-2 coinjection. When the mice were challenged with HSV-1, the cornea epithelial lesions were significantly alleviated by IL-2 coinjection as compared with gD vaccination alone.</p><p><b>CONCLUSION</b>IL-2 cDNA can enhance both the humoral and cellular immune responses, and thus increase the vaccine potency.</p>


Subject(s)
Animals , Female , Mice , Antibodies, Viral , Blood , COS Cells , Cell Proliferation , Chlorocebus aethiops , DNA , Genetics , Herpesvirus 1, Human , Virulence , Hypersensitivity, Delayed , Allergy and Immunology , Immunization , Immunoglobulin G , Blood , Interferon-gamma , Blood , Interleukin-2 , Genetics , Mice, Inbred BALB C , Random Allocation , Th1 Cells , Cell Biology , Transfection , Vaccines, DNA , Allergy and Immunology , Viral Envelope Proteins , Genetics , Viral Vaccines , Allergy and Immunology
3.
Acta Academiae Medicinae Sinicae ; (6): 301-306, 2003.
Article in Chinese | WPRIM | ID: wpr-350104

ABSTRACT

<p><b>OBJECTIVE</b>To develop a therapeutic vaccine against human tumors associated with human papillomavirus type 16E6E7 (HPV16E6E7) which is modified from a Chinese patient of the cervical cancer which possessing the antigenicity and no transforming activity, and explore more active vaccine for inducing cellular immunity with mouse co-stimulatory molecular B7-1 gene.</p><p><b>METHODS</b>The modified E6E7 gene expression plasmid pVR1012-fmE6E7 was constructed and transfected Cos-7 cells, and the E7 protein specific expression was testified by immunofluorescence assay. C57BL/6 mice were immunized intramuscularly with pVR1012-fmE6E7 alone or in combination with B7-1 gene expression plasmid (pcDNA3.1-B7-1). The activity of cytotoxic T lymphocytes (CTLs) was analyzed with 51Cr specific release assay and the specific antibody in sera was analyzed by indirect ELISA. HPV16 positive C57BL/6 tumor cells C3 were inoculated subcutaneously in the vaccinated mice to assay the growth of transplanted tumors.</p><p><b>RESULTS</b>The specific CTLs and antibody from immunized mice were induced efficaciously by the E6E7 gene immunization, and co-administration of B7-1 gene could significantly enhanced the CTLs immune responses of fmE6E7, and protected 33% immunized mice against C3 tumor cells challenge. In contrast, all the mice immunized only with fmE6E7 gene developed transplanted tumors after C3 cells challenge. There was no difference in E7 specific antibody responses between mice immunized with the E6E7 gene only and co-administration with B7-1 gene.</p><p><b>CONCLUSIONS</b>The modified E6E7 gene can be used as target gene for developing DNA vaccine, and B7-1 gene may represent an attractive adjuvant for enhancement of the specific cellular immune responses.</p>


Subject(s)
Animals , Female , Mice , Antibodies, Neoplasm , Allergy and Immunology , B7-1 Antigen , Genetics , Allergy and Immunology , Mice, Inbred C57BL , Neoplasm Transplantation , Oncogene Proteins, Viral , Genetics , Allergy and Immunology , Papillomavirus E7 Proteins , Repressor Proteins , T-Lymphocytes, Cytotoxic , Allergy and Immunology , Transfection , Uterine Cervical Neoplasms , Allergy and Immunology , Pathology , Virology , Vaccines, DNA , Allergy and Immunology
4.
Acta Academiae Medicinae Sinicae ; (6): 67-70, 2002.
Article in Chinese | WPRIM | ID: wpr-280963

ABSTRACT

<p><b>OBJECTIVE</b>The goal of this study was to construct a eukaryotic expression plasmid containing the gene encoding herpes simplex virus type I glycoprotein D (HSV-1, gD) and evaluate its utility for DNA immunization in mice.</p><p><b>METHODS</b>The gD gene was amplified from viral DNA using PCR with EcoR I and BamH I restriction sites encoded on 5' and 3' ends, respectively. The PCR fragment was inserted into the transfer vector pGEM-T Easy. gD was then cut from this vector and inserted into the EcoR I and BamH I sites in the pcDNA3.1 at the multiple cloning sites (MCS). The recombinant plasmid, pcDNA3.1-gD1, was transfected into COS-7 cells using Lipofectamine according to the manufacture's instructions. The expression of the glycoprotein D was analyzed by immunoblotting of the cell lysates. 4-6 weeks old BALB/C mice were given two injections at tibia anterialis muscle, each containing 100 micrograms of plasmid DNA, on days 0 and 15. pcDNA3.1 was used as negative control. Blood samples were taken from all mice at weeks 0, 2, 4, and 6 after the first inoculation. Standard indirect ELISA was employed to evaluate the levels of specific total Ig in serum.</p><p><b>RESULTS</b>The recombinant plasmid was confirmed with restriction digestion and sequencing to contain target gene segment and expressed in COS-7 cells in vitro shown by Western blotting. The pcDNA3.1-gD1 immunized group induced specific antibody response as compared to the negative control, and the titer was about 1:2000.</p><p><b>CONCLUSIONS</b>The recombinant plasmid pcDNA3.1-gD1 is potential to be used as a candidate vaccine, for the treatment of HSV-1 infection.</p>


Subject(s)
Animals , Humans , Mice , COS Cells , Metabolism , Escherichia coli , Genetics , Genetic Vectors , Mice, Inbred BALB C , Vaccines, DNA , Genetics , Allergy and Immunology , Viral Envelope Proteins , Genetics , Allergy and Immunology
SELECTION OF CITATIONS
SEARCH DETAIL